Efavirenz — Membership Pricing

Other medications in Infections

• Emtricitabine
• Entecavir
• Ertapenem
• Erythromycin
• Ethambutol
• Famciclovir
• Fluconazole
• Foscarnet

About Efavirenz

Efavirenz is a vital antiretroviral medication used in the management of HIV infection, helping to reduce the viral load and improve immune health. Understanding your treatment options and how to afford them is crucial. TheDrugClub is dedicated to helping members access essential medications like efavirenz at more manageable prices, ensuring you can prioritize your health without undue financial stress.

Efavirenz is a cornerstone medication in the fight against Human Immunodeficiency Virus (HIV). It is a prescription drug primarily used to treat HIV-1 infection in adults and children, typically as part of a combination regimen with other antiretroviral agents. By effectively suppressing the virus, efavirenz helps to maintain the immune system, prevent disease progression, and improve the overall quality of life for individuals living with HIV.

How Efavirenz Works

Belonging to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz works by targeting a specific enzyme crucial for the HIV life cycle. This enzyme, called reverse transcriptase, is essential for the virus to convert its RNA into DNA, a step necessary for it to replicate and infect new cells. Efavirenz binds to and blocks the activity of reverse transcriptase, thereby preventing the virus from making copies of itself. This action significantly reduces the amount of HIV in the body (viral load) and allows the immune system to recover and function more effectively.

Typical Costs and TheDrugClub Advantage

The cost of efavirenz can vary significantly, depending on whether you are prescribed the brand-name version (Sustiva) or a generic equivalent, your dosage, the pharmacy you choose, and your insurance coverage. Without insurance or a savings program, the retail price for efavirenz can be substantial, posing a significant barrier to consistent treatment. Even with insurance, co-pays and deductibles can add up, making long-term adherence challenging for many.

This is where TheDrugClub offers a valuable solution. Our membership program is designed to provide access to discounted pricing on a wide range of prescription medications, including efavirenz. While TheDrugClub does not act as an insurance provider, our negotiated rates can often lead to considerable savings compared to standard retail prices. We understand that access to life-saving medication should be as straightforward as possible.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Efavirenz is approved for (FDA label)

Efavirenz in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: June 28, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Efavirenz (FDA label)

• Efavirenz Tablets, USP 600 mg 600-mg tablets are yellow, biconvex, capsule-shaped, film-coated tablets, engraved with "ML 12" on one side and plain on the other side. •Tablets: 600 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 13ca3456-e5bf-4bb1-af95-b1378658a358. SPL document ID: f1a4251a-e04d-48aa-ae58-44b30df1de0d. Label effective date: June 28, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Efavirenz (FDA label)

The most significant adverse reactions observed in patients treated with efavirenz are: •psychiatric symptoms [see Warnings and Precautions ( 5.5 )], •nervous system symptoms [see Warnings and Precautions ( 5.6 )], •rash [see Warnings and Precautions ( 5.8 )]. •hepatotoxicity [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (>5%, moderate-severe) are impaired concentration, abnormal dreams, rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharmaceutical Ltd at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, the adverse reaction rates reported cannot be directly compared to rates in other clinical studies and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 13ca3456-e5bf-4bb1-af95-b1378658a358. SPL document ID: f1a4251a-e04d-48aa-ae58-44b30df1de0d. Label effective date: June 28, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Efavirenz (FDA label)

• Efavirenz is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product. • Coadministration of efavirenz with elbasvir and grazoprevir is contraindicated [ see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 ) ]. •Patients with previously demonstrated hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions to any of the components of this product. ( 4 ) •Coadministration of efavirenz with elbasvir/grazoprevir

Source: FDA prescribing information (DailyMed). Set ID: 13ca3456-e5bf-4bb1-af95-b1378658a358. SPL document ID: f1a4251a-e04d-48aa-ae58-44b30df1de0d. Label effective date: June 28, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Efavirenz (FDA label)

• QTc prolongation : Consider alternatives to efavirenz in patients taking other medications with a known risk of Torsade de Pointes or in patients at higher risk of Torsade de Pointes. ( 5.2 ) • Do not use as a single agent or add on as a sole agent to a failing regimen. Consider potential for cross resistance when choosing other agents. ( 5.3 ) •Not recommended with ATRIPLA, which contains efavirenz, emtricitabine, and tenofovir disoproxil fumarate, unless needed for dose adjustment when coadministered with rifampin. ( 5.4 ) • Serious psychiatric symptoms : Immediate medical evaluation is recommended for serious psychiatric symptoms such as severe depression or suicidal ideation. ( 5.5 , 17 ) • Nervous system symptoms (NSS): NSS are frequent and usually begin 1-2 days after initiating therapy and resolve in 2-4 weeks. Dosing at bedtime may improve tolerability.

Source: FDA prescribing information (DailyMed). Set ID: 13ca3456-e5bf-4bb1-af95-b1378658a358. SPL document ID: f1a4251a-e04d-48aa-ae58-44b30df1de0d. Label effective date: June 28, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Efavirenz (FDA label)

Coadministration of efavirenz can alter the concentrations of other drugs and other drugs may alter the concentrations of efavirenz. The potential for drug-drug interactions should be considered before and during therapy. ( 7 ) 7.1 Potential for efavirenz to Affect other Drugs Efavirenz has been shown in vivo to induce CYP3A and CYP2B6. Other compounds that are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when coadministered with efavirenz 7.2 Potential for Other Drugs to Affect efavirenz Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations [see Dosage and Administration ( 2.2 )]. 7.3 QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval.

Source: FDA prescribing information (DailyMed). Set ID: 13ca3456-e5bf-4bb1-af95-b1378658a358. SPL document ID: f1a4251a-e04d-48aa-ae58-44b30df1de0d. Label effective date: June 28, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.